{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:04:56Z","timestamp":1790057096215,"version":"4.0.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Atopic dermatitis (AD) and vitiligo are pediatric immune-mediated inflammatory skin diseases with distinct but potentially overlapping immune mechanisms. Dupilumab targets interleukin (IL)-4 and IL-13 signaling and is effective for moderate-to-severe AD. However, the coexistence, emergence, or progression of vitiligo during dupilumab therapy may create therapeutic challenges when both eczematous inflammation and melanocyte-directed autoimmunity require control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed four children aged 6\u201311 years with AD complicated by pre-existing or emerging vitiligo during dupilumab therapy. Clinical features, timing of vitiligo onset or progression, response to dupilumab, subsequent targeted treatment, follow-up outcomes, and safety data were summarized. Vitiligo was diagnosed clinically and supported by Wood's lamp examination when available.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Two patients had vitiligo before dupilumab initiation, whereas two developed hypopigmented or depigmented lesions during dupilumab treatment. One patient with severe AD showed no obvious improvement after dupilumab; instead, original eczematous lesions became more erythematous and swollen, and new hypopigmented patches appeared around the ankle regions. Dupilumab was discontinued in all patients. Three patients were switched directly to a Janus kinase (JAK) 1 inhibitor. One patient was initially switched to a JAK3\/TEC family kinase inhibitor but later changed to a JAK1 inhibitor because of AD recurrence. During follow-up, all patients showed improvement of AD and stabilization or repigmentation of vitiligo. No serious adverse events were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case series describes a pediatric AD-vitiligo overlap phenotype in which final transition to JAK1 inhibition was associated with improvement of both diseases after dupilumab discontinuation. Causality between dupilumab and vitiligo cannot be established. JAK1 inhibition may be considered in carefully selected children requiring simultaneous control of AD and active vitiligo.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2026.1927668","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:40:36Z","timestamp":1790055636000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: JAK1 inhibition after dupilumab discontinuation in pediatric atopic dermatitis complicated by pre-existing or emerging vitiligo"],"prefix":"10.3389","volume":"14","author":[{"given":"Lijuan","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Dermatology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health , Beijing","place":["China"]},{"name":"Key Laboratory of Major Diseases in Children, Ministry of Education , Beijing","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zigang","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health , Beijing","place":["China"]},{"name":"Key Laboratory of Major Diseases in Children, Ministry of Education , Beijing","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health , Beijing","place":["China"]},{"name":"Key Laboratory of Major Diseases in Children, Ministry of Education , Beijing","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","article-title":"Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6\u201311 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial","volume":"83","author":"Paller","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1146\/annurev-immunol-100919-023531","article-title":"Vitiligo: mechanisms of pathogenesis and treatment","volume":"38","author":"Frisoli","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/pcmr.12949","article-title":"An update on vitiligo pathogenesis","volume":"34","author":"Seneschal","year":"2021","journal-title":"Pigment Cell Melanoma Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"223ra23","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci Transl Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"eaam7710","DOI":"10.1126\/scitranslmed.aam7710","article-title":"Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo","volume":"10","author":"Richmond","year":"2018","journal-title":"Sci Transl Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jdcr.2023.03.025","article-title":"Vitiligo during dupilumab therapy","volume":"36","author":"Picone","year":"2023","journal-title":"JAAD Case Rep"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1111\/jdv.19132","article-title":"Vitiligo induced by dupilumab treatment: a case series","volume":"37","author":"Ren","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1111\/ddg.15564","article-title":"Two cases of dupilumab-induced vitiligo","volume":"22","author":"Farinha","year":"2024","journal-title":"J Dtsch Dermatol Ges"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e280","DOI":"10.1111\/jdv.20279","article-title":"Interactions between dupilumab and vitiligo: a scoping review","volume":"39","author":"Mehta","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1177\/12034754251334569","article-title":"Onset of vitiligo during dupilumab treatment: a systematic review","volume":"29","author":"Branyiczky","year":"2025","journal-title":"J Cutan Med Surg"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","article-title":"Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: results from a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/ped4.12400","article-title":"Biologics and oral small-molecule inhibitors for treatment of pediatric atopic dermatitis: opportunities and challenges","volume":"7","author":"Zhao","year":"2023","journal-title":"Pediatr Investig"},{"key":"B14","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jdermsci.2023.12.008","article-title":"JAK inhibitors for the treatment of vitiligo","volume":"113","author":"Inoue","year":"2024","journal-title":"J Dermatol Sci"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","article-title":"Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo","volume":"387","author":"Rosmarin","year":"2022","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jaad.2022.11.005","article-title":"Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: a randomized phase 2b clinical trial","volume":"88","author":"Ezzedine","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/jdv.15979","article-title":"Development and validation of new diagnostic criteria for atopic dermatitis in children of China","volume":"34","author":"Cheng","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1111\/jdv.19451","article-title":"Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the international vitiligo task force part 1: towards a new management algorithm","volume":"37","author":"van Geel","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1001\/jamadermatol.2014.3324","article-title":"Association of vitiligo and alopecia areata with atopic dermatitis: a systematic review and meta-analysis","volume":"151","author":"Mohan","year":"2015","journal-title":"JAMA Dermatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1111\/jocd.13263","article-title":"Association of atopic dermatitis with vitiligo: a systematic review and meta-analysis","volume":"19","author":"Acharya","year":"2020","journal-title":"J Cosmet Dermatol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13223-021-00597-4","article-title":"Atopic dermatitis and risk of autoimmune diseases: a systematic review and meta-analysis","volume":"17","author":"Lu","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1016\/j.jid.2022.03.013","article-title":"T helper 2 IL-4\/IL-13 dual blockade with dupilumab is linked to some emergent T helper 17-type diseases, including seronegative arthritis and enthesitis\/enthesopathy, but not to humoral autoimmune diseases","volume":"142","author":"Bridgewood","year":"2022","journal-title":"J Invest Dermatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1001\/jamadermatol.2019.0109","article-title":"Assessment of the development of new regional dermatoses in patients treated for atopic dermatitis with dupilumab","volume":"155","author":"Zhu","year":"2019","journal-title":"JAMA Dermatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1159\/000530608","article-title":"Dupilumab-associated psoriasis and psoriasiform manifestations: a scoping review","volume":"239","author":"Su","year":"2023","journal-title":"Dermatology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1111\/jdv.19450","article-title":"Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the international vitiligo task force-part 2: specific treatment recommendations","volume":"37","author":"Seneschal","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1093\/bjd\/ljae385","article-title":"British Association of Dermatologists living guideline for managing people with alopecia areata 2024","volume":"192","author":"Harries","year":"2025","journal-title":"Br J Dermatol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.5114\/ada.2022.122606","article-title":"308-nm Excimer lamp with 0.03% tacrolimus ointment is safe and effective to treat children with non-segmental vitiligo","volume":"39","author":"Li","year":"2022","journal-title":"Postepy Dermatol Alergol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1001\/jamadermatol.2019.0696","article-title":"Treatment outcomes of topical calcineurin inhibitor therapy for patients with vitiligo: a systematic review and meta-analysis","volume":"155","author":"Lee","year":"2019","journal-title":"JAMA Dermatol"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1927668\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:40:43Z","timestamp":1790055643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1927668\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":28,"alternative-id":["10.3389\/fped.2026.1927668"],"URL":"https:\/\/doi.org\/10.3389\/fped.2026.1927668","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"article-number":"1927668"}}